Ragnotti G, Presta M, Riboni L, Zavanella T
J Natl Cancer Inst. 1982 Apr;68(4):669-72.
A newly synthesized beta-adrenoreceptor blocking agent, DL-1-(2-nitro-3-methyl-phenoxy)-3-tert-butylamino-propan-2-ol (ZAMI 1305), administered intragastrically for 6 months induced hepatocellular carcinomas in female outbred Wistar rats in a dose-dependent fashion but was harmless to the livers of male outbred Wistar rats. Experiments with castrated animals confirmed the dependence of the carcinogenic effect of ZAMI 1305 on the hormonal status of the rat. When an isomer of ZAMI 1305, DL-1-(2-nitro-5-methyl-phenoxy)-3-tert-butylamino-propan-2-ol (ZAMI 1327), and DL-practolol, which have pharmacologic activities similar to those of ZAMI 1305, were administered by the same experimental technique as used for ZAMI 1305, no liver tumors appeared either in male or female rats.
一种新合成的β-肾上腺素能受体阻断剂，DL-1-(2-硝基-3-甲基苯氧基)-3-叔丁氨基丙-2-醇（ZAMI 1305），经胃内给药6个月，以剂量依赖方式在雌性远交系Wistar大鼠中诱发肝细胞癌，但对雄性远交系Wistar大鼠的肝脏无害。对去势动物的实验证实了ZAMI 1305的致癌作用依赖于大鼠的激素状态。当采用与ZAMI 1305相同的实验技术给予ZAMI 1305的异构体DL-1-(2-硝基-5-甲基苯氧基)-3-叔丁氨基丙-2-醇（ZAMI 1327）和具有与ZAMI 1305相似药理活性的DL-心得宁时，雄性和雌性大鼠均未出现肝肿瘤。
